Sera Prognostics Names Scott Gleason as New CFO

Gleason brings over 25 years of experience to the company, having previously served as CFO at LarmorBio and NX Prenatal, and as interim CFO at OraSure Technologies. His background also includes leadership roles in investor relations and corporate strategy at Myriad Genetics and Neogen Corporation. CEO Zhenya Lindgardt noted that his expertise in scaling medical products will be vital as the company focuses on commercial execution and expanding access to its biomarker technology.

The current CFO, Austin Aerts, will transition to an advisory role to ensure continuity. Aerts, who has been with the company since 2017, played a central role in guiding Sera Prognostics through its initial public offering and the subsequent transition to public markets. In his new capacity, he will continue to provide strategic support and institutional knowledge during the handoff.